In 2001 Eli Lilly lost its patent on Prozac and the money vanished almost overnight. In 2026 the world’s AI companies face the same cliff every few months — which may explain why the people most worried about AI keep building it faster.
Easier version: read this lesson at A2/B1 level →
Ten items. Work through the four activities — say your answer out loud before you reveal it.
Three terms: open-weight · valuation · the frontier. Say the right one, then reveal.
Read each part. After it, there's a quick check (answer from memory first), then one question to discuss.
Prozac arrived in American pharmacies at the end of the 1980s and became one of the best-known medicines in the world. For its maker, Eli Lilly, it was a remarkable business. A new drug can cost hundreds of millions of dollars to develop, but once it is approved, a patent protects it from copies. By the early 2000s Prozac was bringing in around two and a half billion dollars a year — at its peak, some six or seven hundred million a quarter, and roughly a quarter of the company’s sales.
In August 2001 the patent expired. Generic manufacturers were ready, and their versions went on sale at a fraction of the price. The effect was almost immediate: within weeks, most prescriptions had moved to the cheaper copies, and Lilly’s Prozac revenue collapsed. It never came back. The drug had enjoyed about fourteen years of protected sales; after that, it was a commodity.
For the pharmaceutical industry this was not a surprise but a law of nature. Everyone knows the date their patents end, and the whole business model is built around it: earn back the investment while the protection lasts, and have the next drug ready before the cliff. And the same story helps explain something much newer — why the companies building artificial intelligence cannot stop.
1. Why could Lilly charge high prices for Prozac for so long?
2. What happened after August 2001, and how quickly?
1. Because the patent stopped other companies from making and selling copies of the drug, so Lilly had no direct competition.
2. The patent expired, cheaper generic versions went on sale, and within weeks most prescriptions had switched to them; Lilly’s Prozac revenue collapsed and never recovered.
The leading AI companies — the frontier labs — work a little like drug makers. They spend billions to build a product that is, for a short time, scarce: the most capable model in the world. While it is the best, they have pricing power. The difference is that their protection does not last fourteen years. It lasts three or four months.
Take Anthropic’s Claude Opus 4.7, released in April 2026 as a state-of-the-art model. On one simplified calculation, intelligence at that level cost around four dollars per million tokens (the units in which AI use is measured), and the price stayed there for three or four months. Then cheaper open-weight models, many of them from China, reached a similar level. Within a few months the price for the same level of intelligence had fallen by about three quarters, to roughly one dollar. No patent had expired; the competition simply caught up.
The effect is visible in what customers use. On OpenRouter, a website that lets developers choose between many AI models, the share of European usage going to open-weight models rose, by one estimate, from about 16% to about 60% in a single year. Most people never notice: they use familiar chat products. But underneath many popular apps are the cheap “generics”. For the frontier labs, and for investors who have given them some of the highest valuations in business history, there is only one answer — keep moving the frontier forward, so there is always something new that the copies cannot yet match.
1. In the comparison with medicines, what is the AI equivalent of a patent expiring?
2. What happened to the price of Opus 4.7-level intelligence, and why?
1. Cheaper open-weight models (the “generics”) reaching the same level of capability — which happens after three or four months, not fourteen years.
2. It stayed around four dollars per million tokens for three or four months, then fell by about 75% to roughly one dollar, because open-weight competitors caught up.
Here is the problem. The frontier, where the labs must keep pushing to justify their valuations, is also where the biggest risks are. Several of the people running these companies have said publicly that advanced AI could be dangerous. So the obvious question is: why don’t they just stop?
In September 2026 Anthropic’s chief executive, Dario Amodei, published a long essay. He did not call for a pause, and he did not say his own company would slow down on its own. Instead, he argued that the pace of the whole frontier needed limits — speed limits for everyone — and called for strong economic restrictions on China, to buy time to make AI safe. But any deal with China would be negotiated by President Trump, whose view is very different. “Whoever wins AI wins,” as he put it, describing a race he wants the United States to keep leading.
There is a final complication. The race is not only dangerous; it is also enormously useful. Cheap models are what allow start-ups, and countries without a giant AI company of their own, such as the UK, to build with AI at all. They may want safety — but not a clear winner, and perhaps not even a final settlement, because they gain so much from the competition. So every player may be thinking the same thing: I may not like where this race is going, but I don’t want to lose, and I really don’t want them to win. The question is still open: can anyone leave the race — and if not, who could change its rules?
1. What did Amodei call for — and what did he not call for?
2. Why might smaller countries and start-ups not want the race to end with one clear winner?
1. He called for limits on the pace of the whole frontier (speed limits for everyone) and strong economic restrictions on China; he did not call for a pause, and did not say Anthropic would slow down on its own.
2. Because the competition keeps prices low and gives them cheap, capable models to build with; a single winner could remove that benefit.
Strategy is built on scenarios: what happens if a competitor moves, if prices fall, if we had acted sooner. In speeches, board papers and interviews, senior speakers often drop if and put the verb first. It sounds measured and deliberate — the voice of someone who has thought the scenario through. There are only three patterns to learn.
Rewrite the beginning of each sentence without if. Write the missing words — the rest of the sentence stays the same.
1. If the patent expired early, our revenue would collapse. → early, our revenue would collapse.
2. If we had seen the price data sooner, we would have changed our plan. → the price data sooner, we would have changed our plan.
3. If a customer asks for a refund, the team will process it within two days. → for a refund, the team will process it within two days.
4. If it weren’t for cheap competitors, prices would still be high. → cheap competitors, prices would still be high.
1. Were the patent to expire 2. Had we seen 3. Should a customer ask 4. Were it not for
In 1, Should the patent expire is also possible, but it makes the scenario sound more likely than the original if … expired … would. In 4, never Weren’t it for — the not goes after it.
Complete each gap with the correct form of the verb in brackets. Decide first: imagined future, real possibility, or past that didn’t happen?
1. Had Lilly (find) a replacement drug in time, its 2001 results would have looked very different.
2. Were every lab (agree) to slow down, at least one would still have a reason to break the agreement.
3. Should prices (fall) again this year, the company will need a new way to explain its valuation.
4. Had it not (be) for open-weight models, the start-up could never have afforded to launch.
1. found 2. to agree 3. fall 4. been
1 and 4 are the past that didn’t happen (had + past participle). 2 is imagined (were + to-infinitive). 3 is a real possibility (should + bare verb — no falls, even though prices is the subject).
The head of an AI company is asked at a conference: “If you think this is dangerous, why don’t you stop?” Complete the answer with the words in brackets, using inversion each time. Then deliver it aloud, slowly, as if the whole room is filming you.
“It’s a fair question, so let me answer it directly. (we / stop) tomorrow, the work would not stop with us — it would simply move to companies with fewer safeguards. (a binding international agreement / appear), we will sign it on the first day. (governments / act) five years ago, we might not be having this conversation at all. And (it / not / be) for the competition, prices would be four times higher — so let’s not pretend this race brings nobody any benefit.”
Were we to stop · Should a binding international agreement appear · Had governments acted · Were it not
Now give the same answer with if in every sentence. It is just as correct — but listen to how much more defensive it sounds. Notice too that this is one side of the argument: the Going Deeper tab asks whether “if we stop, someone worse takes over” is a reason or an excuse.
Take these into the Speak tab: a scenario stated with inversion sounds calm and considered — useful under pressure, but a listener may also hear it as a way of avoiding a straight answer.
A note on the figures: sales, prices and usage shares are rounded, and the AI prices and usage shares are simplified estimates from public data; this case is developing week by week.
All of it out loud, against the clock. A race you cannot leave has to be explained to people with very different fears — and scenarios are the language for it.
Present this case to a board that is about to spend heavily on AI. Structure it: how a patent protects a drug → Prozac and the 2001 cliff → the frontier labs and their pricing power → Opus 4.7 and the three-month “patent” → open-weight models and the European shift → why the labs must keep pushing → the safety problem at the frontier → Amodei’s essay and the political reality → the middle powers → the open question.
Finish with one scenario the board should plan for. Use at least five key terms (patent cliff, generic, pricing power, the frontier, open-weight, valuation, commoditise, unilaterally, arms race, incentive) and at least three inverted conditions.
You lead a frontier AI company and are giving evidence to a parliamentary committee. A member says: “Your own leaders say this technology could be dangerous. You keep building it faster. Either you don’t believe the warnings, or you are putting profit before safety. Which is it?”
Answer properly: accept the tension, explain the economics in numbers, say clearly what would make you slow down, and state one scenario with inversion. Then do it again in ninety seconds — the compression is the exercise.
Take a market where a premium product is suddenly being copied cheaply — use one of the examples below or one you know — and explain the situation four ways, one minute each. Notice which room needs scenarios, and which room just wants a straight answer.
Prefer not to use your own organisation? Take one of these instead: